{
    "clinical_study": {
        "@rank": "106086", 
        "brief_summary": {
            "textblock": "To determine the safety profile, assess pharmacokinetic properties (blood levels), and\n      obtain preliminary indication of the antiviral and immunologic effects of recombinant CD4\n      immunoglobulin G (CD4-IgG).\n\n      CD4-IgG may be effective in blocking HIV transmission and spread, that is, CD4-IgG has\n      antiviral effects. Studies done in adult patients with AIDS and AIDS related complex (ARC)\n      have shown that rCD4 can be safely administered by intravenous bolus, intramuscular or\n      subcutaneous injection. No serious or dose-limiting, drug-related toxicities have been\n      observed to date."
        }, 
        "brief_title": "A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "CD4-IgG may be effective in blocking HIV transmission and spread, that is, CD4-IgG has\n      antiviral effects. Studies done in adult patients with AIDS and AIDS related complex (ARC)\n      have shown that rCD4 can be safely administered by intravenous bolus, intramuscular or\n      subcutaneous injection. No serious or dose-limiting, drug-related toxicities have been\n      observed to date.\n\n      Patients receive one intravenous injection the first week, followed by a 6 day washout\n      period and then intravenous injections on a twice weekly basis from week 2 to week 12. The\n      dose per injection may vary. The study evaluates 2 groups: (1) Children 3 months to 5 years\n      of age; (2) Infants 0-3 months of age."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have the following:\n\n          -  HIV-1 infection, or if less than 15 months old, born to mother with HIV-1 infection.\n\n          -  Legally qualified guardian with the ability to sign a written, informed consent form.\n\n          -  Willingness to abstain from all other experimental therapy for HIV-1 infection during\n             the first 12 weeks of the study period.\n\n          -  Anticipated life expectancy of at least 3 months.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prophylactic anti-Pneumocystis carinii pneumonia (PCP) or antifungal therapy.\n\n          -  Gamma globulin as prophylaxis for measles and varicella.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Past or present history of neurological abnormalities including withdrawal syndrome\n             or seizures.\n\n          -  Past or present history of any serious active opportunistic infection including\n             Pneumocystis carinii pneumonia (PCP).\n\n          -  Echocardiogram values > 2 standard deviations from normal.\n\n          -  Hematologic, renal, or hepatic insufficiency.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Zidovudine (AZT).\n\n          -  Intravenous gamma globulin (IVIG) except as prophylaxis for measles and varicella.\n\n          -  Cancer chemotherapy.\n\n          -  Corticosteroids.\n\n          -  Other known immunomodulatory agents.\n\n          -  Other experimental therapy not specifically allowed.\n\n        Patients with the following are excluded:\n\n          -  Hematologic, renal, or hepatic insufficiency.\n\n          -  Past or present history of any serious active opportunistic infection.\n\n        Prior Medication:\n\n        Excluded for a minimum of 3 weeks prior to study entry:\n\n          -  Zidovudine (AZT).\n\n          -  Intravenous gamma globulin (IVIG).\n\n          -  Cancer chemotherapy.\n\n          -  Immunomodulatory agents.\n\n          -  Acyclovir and other experimental therapy.\n\n        Risk Behavior:\n\n        Excluded:\n\n          -  Patients born to substance abusing mothers (including alcohol) during the pregnancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "5 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "18", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000663", 
            "org_study_id": "ACTG 139", 
            "secondary_id": "D0172g"
        }, 
        "intervention": {
            "intervention_name": "CD4-IgG", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulin G", 
                "Immunoglobulins", 
                "Antibodies", 
                "CD4 Immunoadhesins"
            ]
        }, 
        "keyword": [
            "Recombinant Proteins", 
            "Injections, Intravenous", 
            "IgG", 
            "Drug Evaluation", 
            "Acquired Immunodeficiency Syndrome", 
            "Antigens, CD4", 
            "Carrier Proteins"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "UCSD Treatment Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Univ of Miami School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Cook County Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Tulane Univ Med School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Great Neck", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11021"
                    }, 
                    "name": "North Shore Univ Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia Univ Babies' Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Texas Children's Hosp / Baylor Univ"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection", 
        "overall_official": [
            {
                "last_name": "R Yogev", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "W Shearer", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Weintrub P, Yogev R, Conner E, Wilfert K, Mordenti J, Ammann AJ. Safety and pharmacokinetics of recombinant CD4 in children with HIV infection. Int Conf AIDS. 1990 Jun 20-23;6(2):95 (abstract no FB23)"
            }, 
            {
                "PMID": "11069253", 
                "citation": "Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore M, Church J, DeVille J, Fenton T, Graham B, Samson P, Staprans S, McNamara J, Moye J, Maddon PJ, Olson WC. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis. 2000 Dec;182(6):1774-9. Epub 2000 Oct 27."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000663"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1996"
    }, 
    "geocoordinates": {
        "Columbia Univ Babies' Hosp": "40.714 -74.006", 
        "Cook County Hosp": "41.878 -87.63", 
        "North Shore Univ Hosp": "40.801 -73.728", 
        "Texas Children's Hosp / Baylor Univ": "29.76 -95.369", 
        "Tulane Univ Med School": "29.951 -90.072", 
        "UCSD Treatment Ctr": "32.715 -117.157", 
        "Univ of Miami School of Medicine": "25.789 -80.226"
    }
}